Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

BACKGROUND: Cytomegalovirus end-organ disease can be prevented by giving ganciclovir when viraemia is detected in allograft recipients. Values of viral load correlate with development of end-organ disease and are moderated by pre-existing natural immunity. Our aim was to determine whether vaccine-in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Griffiths, Paul D, Stanton, Anna, McCarrell, Erin, Smith, Colette, Osman, Mohamed, Harber, Mark, Davenport, Andrew, Jones, Gareth, Wheeler, David C, O'Beirne, James, Thorburn, Douglas, Patch, David, Atkinson, Claire E, Pichon, Sylvie, Sweny, Paul, Lanzman, Marisa, Woodford, Elizabeth, Rothwell, Emily, Old, Natasha, Kinyanjui, Ruth, Haque, Tanzina, Atabani, Sowsan, Luck, Suzanne, Prideaux, Steven, Milne, Richard SB, Emery, Vincent C, Burroughs, Andrew K
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Lancet Publishing Group 2011
Gaiak:
Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3075549/
https://ncbi.nlm.nih.gov/pubmed/21481708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(11)60136-0
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak